Therapy News and Research

RSS

CTRC-AACR San Antonio Breast Cancer Symposium to honor two leading breast cancer researchers

The CTRC-AACR San Antonio Breast Cancer Symposium will honor two leading breast cancer researchers when it holds its 32nd annual meeting Dec. 9-13, in San Antonio.

8 Oct 2009

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.

8 Oct 2009

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

AVANIR Pharmaceuticals, Inc. today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) announcing that it intends to grant the Company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia™ well into 2025.

8 Oct 2009

Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

NCI awards BioMarker Strategies a SBIR contract to develop its SnapPath live-tumor-cell testing system

BioMarker Strategies, LLC announced today that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute to develop the SnapPath™ live-tumor-cell testing system. BioMarker Strategies is developing the SnapPath™ system to enable oncologists to determine the most effective drug treatment for their cancer patients.

7 Oct 2009

Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis

Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.

7 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

Research study to determine association of CYP2D6 variation with tamoxifen therapy

Among women with early stage breast cancer, genetic variation of a certain enzyme appears to be associated with clinical outcomes for women treated with tamoxifen, according to a study in the October 7 issue of JAMA.

7 Oct 2009

Free educational brochure on physical therapy

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, today announced that a free educational brochure on the benefits of physical therapy is available to celebrate October as "National Physical Therapy Month," as designated by the American Physical Therapy Association.

7 Oct 2009

FDA reviews Fibrocell Science's BLA for azfibrocel-T

Isolagen, Inc. has reorganized and emerged from bankruptcy as Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on developing regenerative fibroblast cells for aesthetic, medical and scientific applications.

7 Oct 2009

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced completion of a research report concerning its fluorescent stem cells, http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf. This report revealed transfer of fluorescent to differentiated cells including chondrocytes, cells responsible for making cartilage.

7 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009

Brain injuries in Ontario's construction industry are highest in August and October

August may be the cruellest month for brain injuries in Ontario's construction industry, but a new study shows October is not far behind.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

Vaccination can lower the risks of allergy in children

Vaccination can lower children's risk of allergy. Cathleen Muche-Borowski and her coauthors present a clinical practice guideline for allergy prevention in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2009; 106[39]: 625-31).

7 Oct 2009

Therapy News and Research

CTRC-AACR San Antonio Breast Cancer Symposium to honor two leading breast cancer researchers

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

Entest BioMedical applies for Phase II grant from National Cancer Institute

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

FDA approves Daiichi Sankyo's sNDA for Welchol

NCI awards BioMarker Strategies a SBIR contract to develop its SnapPath live-tumor-cell testing system

Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Research study to determine association of CYP2D6 variation with tamoxifen therapy

Free educational brochure on physical therapy

FDA reviews Fibrocell Science's BLA for azfibrocel-T

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

Brain injuries in Ontario's construction industry are highest in August and October

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Vaccination can lower the risks of allergy in children

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News